The Galien Forum USA 2018

October 25th 2018
Alexandria Center for Life Science – New York

 The Galien Forum, held every autumn at Alexandria Center for Life Science – New York, offers a full day of spirited discussions with Nobel Laureates, top policymakers, and leading industry executives who offer perspectives on the most significant health challenges of our time while highlighting the latest research and clinical pathways toward diagnosis, treatment, and cure.


Novel Approaches to Combatting Opioid Addiction

07:45 am – 08:50 am

Chronic pain is a prevalent but frequently under‐reported condition affecting some 75 million Americans each year, more than the incidence of diabetes, heart disease and cancer combined. It is the leading cause of long‐term disability in the US and accounts for a major share of the physician visits, hospital admissions, prescription drug Rx and other expenditures that drive up overall health costs…

Panel Introduction    Register

Pr. Robert S. Langer, MD
David Koch Institute Professor
Massachusetts Institute of Technology

Dr. Patrice A. Harris, MD, MA
American Medical Association

Michael Heffernan
Collegium Pharmaceutical

Pr. Corey McCann, MD, PhD
Founder and Chief Executive Officer
Pear Therapeutics

Panelist bios


Cancer in a Time of Disruption

08:50 am – 09:55 am

Over the past decade, we have witnessed a significant paradigm shift in the treatment of cancer, largely driven by the unprecedented pace of innovation and discovery in oncology.

Panel Introduction    Register

Joel S. Marcus
Executive Chairman & Founder
Alexandria Real
Estate Equities, Inc./
Alexandria Venture Investments
Alexandria Summit

Lynne Zydowsky, PhD
Chief Science Officer
Alexandria Real
Estate Equities, Inc./
Alexandria Venture Investments
President and Co-Founder
Alexandria Summit

Alexis Borisy
Third Rock Ventures

Lee N. Newcomer, MD
Lee Newcomer Consulting LLC
Former Senior Vice President
Oncology and Genetics

David Schenkein, MD
Chief Executive Officer
Agios Pharmaceuticals

Panelist bios


Making Medicines Affordable

10:15 am – 11:20 am

Progress in the science of drug discovery has made medicines a vital element in the therapeutic arsenal against disease. Since private enterprise has proven to be the predominant source of innovative therapies, the up‐front costs of research and development lead to increased tension between patients desiring new treatments and industry’s need for financial returns in order to offset prior investment and make new high‐risk longterm investment in research…

Panel Introduction    Register

Michael Rosenblatt, MD
Chief Medical Officer
Flagship Pioneering

Sir Andrew Dillon
Chief Executive
National Institute for Health
and Care Excellence (NICE)

John Furey
Chief Operating Officer
Spark Therapeutics Inc.

Scott Howel, MD, MBA
Vice‐President and Head,
US Market Access
Novartis Pharmaceuticals Inc.

Gary P. Pisano, PhD
Harry E. Figgie Professor
of Business Administration
Harvard Business School

Kent Rogers, MBA
Senior Vice President,
Industry Relations

UnitedHealth Group Inc.

Panelist bios


Keynote Anna K. Abram

11:20 am – 12:25 pm

As Deputy Commissioner for Policy, Planning, Legislation and Analysis, Anna Abram plays a critical role in overseeing the development and implementation of key policy initiatives and provides strategic policy direction to advance FDA’s mission and vision of protecting and promoting public health.

Keynote Introduction    Register

Anna K. Abram
Deputy Commissioner for Policy,
Planning, Legislation and Analysis


Sue Desmond-Hellmann, MD, MPh
Chief Executive Officer
Bill & Melinda Gates Foundation
Prix Galien USA Committee Chair


What’s Holding Back the Technology Revolution in Clinical Trials?

01:35 pm – 02:40 pm

Technology is revolutionizing clinical trials, and in the process transforming what is possible in terms of drug development, patient engagement, and insight. Digitization of clinical trial processes has been proven to reduce data variance, increase patient compliance, and decrease site monitoring costs in clinical trials. According to a 2016 Validic study of 166 executives at pharma and biotech companies, contract research organizations, and others in the clinical trial space, 64% have used digital technologies in clinical trials, and 97% plan to in the next five years.

Panel Introduction    Register

Mauro Ferrari, PhD
Ernest Cockrell Jr. Presidential
Distinguished Chair President
and Chief Executive Officer,
Houston Methodist Research
Executive Vice President,
Houston Methodist Hospital System

Steve Rosenberg
Senior Vice President and General Manager
Oracle Health Sciences

Marc M. Boutin, JD
Chief Executive Officer
National Health Council

Gerard G. Nahum, MD
Vice President of Global Clinical Development
for Medical Devices & eHealth

Bayer Pharmaceuticals

Panelist bios


The Promise of Gene Therapy

02:40 pm – 03:45pm

Ever since the achievement of sequencing the human genome, scientists have had the unprecedented opportunity to characterize and understand rare diseases caused by a single faulty gene. As a result, breakthrough approaches to addressing those diseases are emerging with high frequency. This revolution in discovery science has become evident in the past year, with the FDA approval of Luxturna…

Panel Introduction    Register

Mikael Dolsten, MD, PhD
President Worldwide Research and Development
Pfizer Inc.

Katherine A. High
President and head of Research and Development
Spark Therapeutics

Brian Kaspar, PhD
Senior Vice President and Chief Scientific Officer
AveXis, a Novartis Company

Philip D. Gregory, Dr
Chief Scientific Officer
Bluebird bio

Peter Marks, MD, PhD
Center for Biologics Evaluation and Research, FDA

Gaurav Shah, MD
President and Chief Executive Officer
Rocket Pharmaceuticals Inc.

Panelist bios


The Gut Microbiome: Opportunities and Challenge

03:45 pm – 04:50 pm

The gut microbiome is formally defined as the genomes of the microbes that live inside the gut. It is a complex, interactive, multispecies microbial community composed of bacteria, fungi, archaea, and viruses. While the vast majority of the gut microbiome is composed of just 30-40 bacterial species, there more than 1,000 in total, containing about 100x the number of genes as can be found in the human genome.

Panel Introduction    Register

Nancy A. Thornberry
Chief Executive Officer

Michael Fischbach
Associate Professor of Bioengineering
Stanford University

Dan R. Littman, MD, PhD
Vedanta Biosciences

Sarkis K. Mazmanian, PhD
Louis & Nelly Soux Professor of Microbiology Division
of Biology & Biological Engineering
California Institute of Technology

Bernat Olle, PhD
Chief Executive Officer
Vedanta Biosciences

Panelist bios

MedStartUp PANEL

How is Data Science Disrupting the Healthcare Landscape, Modernizing R&D, and Enhancing Access Models ?

12:30 pm – 01:30 pm

There is no question that more information – data – can yield better results. But how we synthesize, use, and act on that complex and often misinterpreted data holds the key to the future of R&D and healthcare. Data science is helping bridge the gap between clinical, regulatory, and pharmacovigilance approaches; between drug developers and healthcare providers; and between clinicians and patients. This means new ways to innovate with compounds in the pipeline, transformed stakeholder collaboration, and better health outcomes.

Panel Introduction  Register

MD, PHD, Executive Vice President & Head of R&D,